STADA Arzneimittel AG Logo

STADA Arzneimittel AG

A leading European manufacturer of generics, consumer healthcare, and specialty pharmaceuticals.

SAZ | HM

Overview

Corporate Details

ISIN(s):
DE0007251803 (+1 more)
LEI:
529900FMTTLMH0P0DL10
Country:
Germany
Address:
Stadastraße 2 - 18, 61118 Bad Vilbel
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

STADA Arzneimittel AG is a global pharmaceutical company operating with a three-pillar strategy consisting of Generics, Consumer Healthcare, and Specialty Pharmaceuticals. The company is a leading European player in its core segments, ranking as the fourth-largest manufacturer of both generics and consumer healthcare products. Its Generics division focuses on providing affordable medicines. The Consumer Healthcare business is driven by a portfolio of strong regional and 'Local Hero' brands. The Specialty Pharmaceuticals segment develops and markets innovative treatments for specific conditions, including biologic therapies. With a heritage rooted in pharmacies and dating back to 1895, STADA's purpose is to be a trusted partner in caring for people's health.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-08-20 00:00
Post-Annual General Meeting Information
Datum:20.08.2025
German 9.6 KB
2025-08-11 00:00
Annual Report
Datum:11.08.2025
German 2.2 MB
2025-07-07 00:00
Post-Annual General Meeting Information
§§ 264 Abs. 3, 264b HGB zum Geschäftsjahr vom 01.01.2024 bis zum 31.12.2024
German 5.6 KB
2025-02-04 00:00
Annual / Quarterly Financial Statement
Jahresabschluss zum Geschäftsjahr vom 01.01.2023 bis zum 31.12.2023
German 564.0 KB
2025-01-21 00:00
Annual Report
Konzernabschluss zum Geschäftsjahr vom 01.01.2023 bis zum 31.12.2023
German 1.8 MB
2024-02-14 00:00
Annual Report
Jahresabschluss zum Geschäftsjahr vom 01.01.2022 bis zum 31.12.2022
German 536.7 KB
2024-01-10 00:00
Annual Report
Konzernabschluss zum Geschäftsjahr vom 01.01.2022 bis zum 31.12.2022
German 1.5 MB
2023-02-23 14:15
Report Publication Announcement
English 3.9 KB
2023-02-23 11:25
Report Publication Announcement
English 4.0 KB
2023-02-23 00:00
Report Publication Announcement
Hinweis auf Konzernabschluss vom 01.01.2022 bis zum 31.12.2022
German 5.7 KB
2023-02-23 00:00
Report Publication Announcement
Hinweis auf Jahresfinanzbericht vom 01.01.2022 bis zum 31.12.2022
German 5.7 KB
2022-09-27 00:00
Annual / Quarterly Financial Statement
Ergänzung der Veröffentlichung vom 12.04.2022
German 2.2 KB
2022-08-17 09:49
Report Publication Announcement
English 4.0 KB
2022-08-17 00:00
Report Publication Announcement
Hinweis auf Halbjahresfinanzbericht vom 01.01.2022 bis zum 30.06.2022
German 5.7 KB
2022-05-10 00:00
Regulatory News Service
Konzernabschluss zum Geschäftsjahr vom 01.01.2021 bis zum 31.12.2021
German 911.5 KB

Automate Your Workflow. Get a real-time feed of all STADA Arzneimittel AG filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for STADA Arzneimittel AG

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for STADA Arzneimittel AG via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

C4 Therapeutics, Inc. Logo
Developing protein degrader medicines to treat cancer and other serious diseases.
United States of America
CCCC
Cabaletta Bio, Inc. Logo
Develops engineered T cell therapies for a curative reset in autoimmune diseases.
United States of America
CABA
Cadrenal Therapeutics, Inc. Logo
Developing novel anticoagulant therapies for high-risk cardiovascular patients.
United States of America
CVKD
CalciMedica, Inc. Logo
Develops CRAC channel inhibitors for critical illnesses like acute pancreatitis & AKI.
United States of America
CALC
Calidi Biotherapeutics, Inc. Logo
Develops immunotherapies using stem cells to deliver oncolytic viruses against solid tumors.
United States of America
CLDI
Calliditas Therapeutics Logo
Develops and commercializes novel treatments for rare renal and hepatic diseases like IgA nephropathy.
Sweden
CALTX
CALTH. Inc Logo
Develops AI-powered rapid diagnostic solutions for point-of-care and self-testing.
South Korea
402420
CAMBRIDGE NUTRITIONAL SCIENCES PLC Logo
Develops and manufactures diagnostic tests for food sensitivity and gut health.
United Kingdom
CNSL
Camp4 Therapeutics Corp Logo
Developing RNA-based therapies to upregulate genes for rare metabolic and CNS disorders.
United States of America
CAMP
Camurus Logo
Develops long-acting medicines for severe chronic diseases using advanced drug delivery.
Sweden
CAMX

Talk to a Data Expert

Have a question? We'll get back to you promptly.